DiagNodus Ltd is a medical diagnostics company which is pioneering the development of novel non-invasive methods to test for colorectal diseases. Producing patient-acceptable highly sensitive diagnostic solutions is the central philosophy of the company.
DiagNodus devices will provide a simple and reliable tool for diagnosis, monitoring and treatment efficiency assessment in the area of inflammatory bowel disease (IBD). They will also save lives by making more efficient screening strategies for colorectal cancer (CRC) possible.
DiagNodus was founded in April 2011 by a group of scientists with extensive experience working in the field of colorectal disease. Their aim was to develop entirely non-invasive methods of diagnosing and monitoring diseases which could be used by patients in their own home. In October 2011 DiagNodus has become the first company selected for participation in the Atlantic Accelerator fast track to commercialisation programme. The company currently operates from laboratories at the Babraham Research Campus in Cambridge, UK.
DiagNodus is in the process of validating and refining its innovative technology through a series of clinical trials. Analysis of samples taken from patients combines application of molecular and cytological approaches. The company is focused on translating basic research into device technology enabling self-testing by individuals for disease diagnosis, monitoring and screening purposes.